RecruitingPhase 3NCT07361510
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Sponsor: Bristol-Myers Squibb
Galveston, TX · Houston, TX · San Antonio, TX · +38 more sites